Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
We aim to characterize the metabolic changes associated with early response to radiation therapy in a prostate cancer mouse model by 2-deoxy-2-[<sup>18</sup>F]fluoro-d-glucose ([<sup>18</sup>F]FDG) and [<sup>11</sup>C]acetate ([<sup>11</sup>C]ACT) positron emission tomography, with nuclear magnetic resonance (NMR) metabolomics corroboration.
|
29125557 |
2017 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
Allele and genotype frequencies of a promoter single nucleotide polymorphism (SNP) in ACT gene were investigated in patients with benign prostate hypertrophy (BHP) or PCa and controls.
|
18383875 |
2008 |
Malignant neoplasm of prostate
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Allele and genotype frequencies of a promoter single nucleotide polymorphism (SNP) in ACT gene were investigated in patients with benign prostate hypertrophy (BHP) or PCa and controls.
|
18383875 |
2008 |
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
To evaluate the diagnostic utility of free PSA (fPSA) and complexed PSA forms for identification of men with PCa in the low PSA range of <4 microg/l, total PSA (tPSA), alpha(1)-antichymotrypsin complexed PSA (PSA-ACT) and fPSA (Roche Elecsys [ES] system) as well as tPSA and complexed PSA (cPSA) (Bayer Immuno 1 system) were measured in archival serum samples from 31 untreated patients with PCa, 66 patients with BPH, and 90 men without prostatic disease.
|
11477592 |
2001 |
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Our objective was to investigate the presence of prostate specific antigen (PSA) and alpha-1-antichymotrypsin (ACT) mRNA and protein in prostate cancer cell lines, and the complexing characteristics of expressed PSA.
|
9568677 |
1998 |
Psychotic Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
Clients with psychosis who need ACT may benefit from Flexible ACT through improved social functioning.
|
29373933 |
2018 |
Nonorganic psychosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
Clients with psychosis who need ACT may benefit from Flexible ACT through improved social functioning.
|
29373933 |
2018 |
Psychotic Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
In this first RCT of a psychological therapy with depression as the primary outcome, ACT is a promising intervention for depression in the context of psychosis.
|
27894822 |
2017 |
Nonorganic psychosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
In this first RCT of a psychological therapy with depression as the primary outcome, ACT is a promising intervention for depression in the context of psychosis.
|
27894822 |
2017 |
Psychotic Disorders
|
0.330 |
GeneticVariation
|
group |
BEFREE |
The objective of this study was to examine the effect of APOE4 and alpha1-antichymotrypsin/AA (ACT/AA) genotypes on time to psychosis onset in subjects with AD.
|
11936240 |
2002 |
Nonorganic psychosis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to examine the effect of APOE4 and alpha1-antichymotrypsin/AA (ACT/AA) genotypes on time to psychosis onset in subjects with AD.
|
11936240 |
2002 |
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.
|
18383875 |
2008 |
Lipoidosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.
|
17175557 |
2007 |
Lipoidosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay.
|
16919414 |
2006 |
Lipoidosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
|
15342952 |
2005 |
Diabetic Retinopathy
|
0.210 |
Biomarker
|
disease |
BEFREE |
An in vitro assay revealed that the human homologue SERPINA3 increased the transendothelial permeability of retinal microvascular endothelial cells, which may be involved in the pathogenesis of diabetes and/or diabetic retinopathy.
|
23545169 |
2013 |
Diabetic Retinopathy
|
0.210 |
Biomarker
|
disease |
CTD_mouse |
Anti-inflammatory and antioxidant effects of SERPINA3K in the retina.
|
19324842 |
2009 |
Liver Cirrhosis, Experimental
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Inflammation
|
0.200 |
Therapeutic
|
phenotype |
CTD_mouse |
Anti-inflammatory and antioxidant effects of SERPINA3K in the retina.
|
19324842 |
2009 |
Retinal Diseases
|
0.200 |
Therapeutic
|
group |
CTD_mouse |
Anti-inflammatory and antioxidant effects of SERPINA3K in the retina.
|
19324842 |
2009 |
Liver Cirrhosis, Experimental
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Identification of fibrosis-relevant proteins using DIGE (difference in gel electrophoresis) in different models of hepatic fibrosis.
|
15650968 |
2005 |
AMYOTROPHIC LATERAL SCLEROSIS 1
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.
|
11796754 |
2002 |
Amyotrophic Lateral Sclerosis, Sporadic
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.
|
11796754 |
2002 |
Amyotrophic Lateral Sclerosis, Familial
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.
|
11796754 |
2002 |
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Participants had adequately controlled asthma (mean ACT or cACT score = 21.6 ± 2.8) at baseline.
|
31371165 |
2020 |